Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Buprenorphine for office-based practice: consensus conference overview.

Thomas R Kosten1, David A Fiellin,

  • 1Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06516, USA. thomas.kosten@yale.edu

The American Journal on Addictions
|June 19, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anxiety, Bipolar, Depressive, and Schizophrenia Diagnoses Among Patients Receiving Addiction Treatment in the United States, 2006-2022: A Descriptive Study.

Substance use & addiction journal·2026
Same author

Best Practices for Hospital-Based Initiation of Medications for Opioid Use Disorder: A Consensus Statement.

JAMA network open·2026
Same author

Brain penetrant calcium channel blockers do not reduce alcohol consumption: Converging results from two large independent cohort studies using electronic health records.

medRxiv : the preprint server for health sciences·2026
Same author

Latent classes of sleep deficiency and correlates among patients receiving methadone treatment: A longitudinal study.

Addiction (Abingdon, England)·2026
Same author

An adapted brief negotiation interview for alcohol and cannabis use among assault-injured emerging adults: A randomized pilot trial protocol.

Contemporary clinical trials·2026
Same author

Bridging genomics and pharmacoepidemiology to expand treatment options for alcohol use disorder.

Alcohol, clinical & experimental research·2026

Buprenorphine shows promise for office-based addiction treatment in the U.S., building on international successes. Physician training and access are crucial for its widespread adoption in treating opiate dependence.

Area of Science:

  • Addiction Medicine
  • Psychiatry
  • Public Health

Background:

  • Buprenorphine is an effective medication for opioid addiction treatment.
  • International experience demonstrates success with office-based buprenorphine treatment.
  • American psychiatrists require training to effectively utilize buprenorphine.

Purpose of the Study:

  • To inform practitioners about global successes with office-based buprenorphine.
  • To outline challenges in implementing buprenorphine in U.S. general practice.
  • To present U.S. studies on buprenorphine for detoxification and maintenance.

Main Methods:

  • Overview of a March 2003 conference on the U.S. buprenorphine implementation program.
  • Review of international case studies (France, Australia).

Related Experiment Videos

  • Presentation of U.S. community-based study findings.

    • Main Results:

    • Buprenorphine has demonstrated utility and promise for opioid addiction treatment in the U.S.
    • International data supports the efficacy of office-based buprenorphine.
    • National monitoring programs are established to assess public health impact.

    Conclusions:

    • Widespread adoption of buprenorphine requires physician education and engagement.
    • Increased physician participation is vital for patient access to buprenorphine/naloxone.
    • A three-year window necessitates urgent physician recruitment for this treatment opportunity.